Evidence map›Paper›PMID 25329456›Full record

ArticlePloS one2014

Deletion of thioredoxin interacting protein (TXNIP) augments hyperoxia-induced vaso-obliteration in a mouse model of oxygen induced-retinopathy.

Mohammed A Abdelsaid, Suraporn Matragoon, Adviye Ergul, Azza B El-Remessy

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Deletion of p75Scientific reports · 2018
    Article
  6. Adenosine AMolecular medicine (Cambridge, Mass.) · 2018
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Mohammed A AbdelsaidClinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, United States of America; Department of Physiology, Georgia Regents University, Augusta, Georgia, United States of America; Charlie Norwood VA Medical Center, Augusta, Georgia, United States of America.
Suraporn MatragoonClinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, United States of America; Culver Vision Discovery Institute, Augusta, Georgia, United States of America; Charlie Norwood VA Medical Center, Augusta, Georgia, United States of America.
Adviye ErgulClinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, United States of America; Department of Physiology, Georgia Regents University, Augusta, Georgia, United States of America; Charlie Norwood VA Medical Center, Augusta, Georgia, United States of America.
Azza B El-RemessyClinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, United States of America; Culver Vision Discovery Institute, Augusta, Georgia, United States of America; Charlie Norwood VA Medical Center, Augusta, Georgia, United States of America.
Augusta University · USCharlie Norwood VA Medical Center · USUniversity of Georgia · US

Funding

Vascular Injury and Recovery in Diabetic Ischemic StrokeR01NS083559 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ERGUL, ADVIYE · 2014 to 2018
$1.9M
Molecular Mechanisms of diabetic retinopathyR01EY022408 · NEI · UNIVERSITY OF GEORGIA · PI EL-REMESSY, AZZA B · 2012 to 2016
$1.5M
BLRD VA I01 BX000347NEI NIH HHS R01 EY022408NEI NIH HHS R01-EY022408NINDS NIH HHS R01 NS083559NINDS NIH HHS R01NS083559
6 · The paper itself

Abstract

We have recently shown that thioredoxin interacting protein (TXNIP) is required for VEGF-mediated VEGFR2 receptor activation and angiogenic signal. Retinas from TXNIP knockout mice (TKO) exhibited higher cellular antioxidant defense compared to wild type (WT). This study aimed to examine the impact of TXNIP deletion on hyperoxia-induced vaso-obliteration in ischemic retinopathy. TKO and WT pups were subjected to oxygen-induced retinopathy model. Retinal central capillary dropout was measured at p12. Retinal redox and nitrative state were assessed by reduced-glutathione (GSH), thioredoxin reductase activity and nitrotyrosine formation. Western blot and QT-PCR were used to assess VEGF, VEGFR-2, Akt, iNOS and eNOS, thioredoxin expression, ASK-1 activation and downstream cleaved caspase-3 and PARP in retinal lysates. Retinas from TKO mice exposed to hyperoxia showed significant increases (1.5-fold) in vaso-obliteration as indicated by central capillary drop out area compared to WT. Retinas from TKO showed minimal nitrotyrosine levels (10% of WT) with no change in eNOS or iNOS mRNA expression. There was no change in levels of VEGF or activation of VEGFR2 and its downstream Akt in retinas from TKO and WT. In comparison to WT, retinas from TKO showed significantly higher level of GSH and thioredoxin reductase activity in normoxia but comparable levels under hyperoxia. Exposure of TKO to hyperoxia significantly decreased the anti-apoptotic thioredoxin protein (∼ 50%) level compared with WT. This effect was associated with a significant increase in activation of the apoptotic ASK-1, PARP and caspase-3 pathway. Our results showed that despite comparable VEGF level and signal in TKO, exposure to hyperoxia significantly decreased Trx expression compared to WT. This effect resulted in liberation and activation of the apoptotic ASK-1 signal. These findings suggest that TXNIP is required for endothelial cell survival and homeostasis especially under stress conditions including hyperoxia.

Indexed as

AnimalsAntioxidantsApoptosisCarrier ProteinsDisease Models, AnimalGene ExpressionHumansHyperoxiaMiceMice, KnockoutOxidation-ReductionOxygenRetinaRetinopathy of PrematuritySignal TransductionThioredoxinsAntioxidantsCarrier ProteinsOxygenThioredoxinsTxnip protein, mouseVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Identifiers

PMID25329456
PMCPMC4199686
OpenAlexW2081530424

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.